vs
Side-by-side financial comparison of CLEAN HARBORS INC (CLH) and GENMAB A/S (GMAB). Click either name above to swap in a different company.
CLEAN HARBORS INC is the larger business by last-quarter revenue ($1.5B vs $925.0M, roughly 1.6× GENMAB A/S). GENMAB A/S runs the higher net margin — 36.3% vs 5.8%, a 30.6% gap on every dollar of revenue. On growth, GENMAB A/S posted the faster year-over-year revenue change (18.7% vs 4.8%). GENMAB A/S produced more free cash flow last quarter ($327.0M vs $233.3M).
Clean Harbors, Inc., headquartered in Norwell, Massachusetts, is a provider of waste management and industrial services for commercial customers, specializing in the collection, transportation, treatment and disposal of hazardous waste, but also offering services for non-hazardous waste. The company has 870 operating locations in 630 properties in the U.S. and Canada including a network of over 100 waste disposal facilities such as incinerators, landfills, treatment, storage and disposal faci...
Genmab A/S is a Danish biotechnology company, founded in February 1999 by Florian Schönharting, at the time managing director of BankInvest Biomedical venture fund. The company is based in Copenhagen, Denmark – internationally, it operates through the subsidiaries Genmab B.V. in Utrecht, The Netherlands, Genmab U.S., Inc. in Princeton, New Jersey, US, Genmab K.K. in Tokyo, Japan, Genmab Germany GmbH in München, Germany and Genmab (Suzhou) Co., Ltd. in Suzhou, China. Genmab is listed on the Co...
CLH vs GMAB — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.5B | $925.0M |
| Net Profit | $86.6M | $336.0M |
| Gross Margin | 30.6% | 93.8% |
| Operating Margin | 10.6% | 38.9% |
| Net Margin | 5.8% | 36.3% |
| Revenue YoY | 4.8% | 18.7% |
| Net Profit YoY | 3.1% | 65.5% |
| EPS (diluted) | $1.62 | $5.42 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.5B | — | ||
| Q3 25 | $1.5B | — | ||
| Q2 25 | $1.5B | $925.0M | ||
| Q1 25 | $1.4B | — | ||
| Q4 24 | $1.4B | — | ||
| Q3 24 | $1.5B | — | ||
| Q2 24 | $1.6B | $779.0M | ||
| Q1 24 | $1.4B | — |
| Q4 25 | $86.6M | — | ||
| Q3 25 | $118.8M | — | ||
| Q2 25 | $126.9M | $336.0M | ||
| Q1 25 | $58.7M | — | ||
| Q4 24 | $84.0M | — | ||
| Q3 24 | $115.2M | — | ||
| Q2 24 | $133.3M | $203.0M | ||
| Q1 24 | $69.8M | — |
| Q4 25 | 30.6% | — | ||
| Q3 25 | 32.3% | — | ||
| Q2 25 | 33.3% | 93.8% | ||
| Q1 25 | 28.6% | — | ||
| Q4 24 | 29.9% | — | ||
| Q3 24 | 31.0% | — | ||
| Q2 24 | 33.3% | 96.4% | ||
| Q1 24 | 29.5% | — |
| Q4 25 | 10.6% | — | ||
| Q3 25 | 12.5% | — | ||
| Q2 25 | 13.6% | 38.9% | ||
| Q1 25 | 7.8% | — | ||
| Q4 24 | 9.6% | — | ||
| Q3 24 | 12.6% | — | ||
| Q2 24 | 13.9% | 30.3% | ||
| Q1 24 | 9.1% | — |
| Q4 25 | 5.8% | — | ||
| Q3 25 | 7.7% | — | ||
| Q2 25 | 8.2% | 36.3% | ||
| Q1 25 | 4.1% | — | ||
| Q4 24 | 5.9% | — | ||
| Q3 24 | 7.5% | — | ||
| Q2 24 | 8.6% | 26.1% | ||
| Q1 24 | 5.1% | — |
| Q4 25 | $1.62 | — | ||
| Q3 25 | $2.21 | — | ||
| Q2 25 | $2.36 | $5.42 | ||
| Q1 25 | $1.09 | — | ||
| Q4 24 | $1.55 | — | ||
| Q3 24 | $2.12 | — | ||
| Q2 24 | $2.46 | $3.13 | ||
| Q1 24 | $1.29 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $127.4M | $1.3B |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $2.7B | $5.3B |
| Total Assets | $7.6B | $6.5B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $127.4M | — | ||
| Q3 25 | $91.2M | — | ||
| Q2 25 | $98.9M | $1.3B | ||
| Q1 25 | $105.9M | — | ||
| Q4 24 | $102.6M | — | ||
| Q3 24 | $82.4M | — | ||
| Q2 24 | $91.3M | $622.0M | ||
| Q1 24 | $104.8M | — |
| Q4 25 | $2.7B | — | ||
| Q3 25 | $2.8B | — | ||
| Q2 25 | $2.7B | $5.3B | ||
| Q1 25 | $2.6B | — | ||
| Q4 24 | $2.6B | — | ||
| Q3 24 | $2.5B | — | ||
| Q2 24 | $2.4B | $4.4B | ||
| Q1 24 | $2.3B | — |
| Q4 25 | $7.6B | — | ||
| Q3 25 | $7.5B | — | ||
| Q2 25 | $7.4B | $6.5B | ||
| Q1 25 | $7.2B | — | ||
| Q4 24 | $7.4B | — | ||
| Q3 24 | $7.3B | — | ||
| Q2 24 | $7.1B | $5.6B | ||
| Q1 24 | $6.9B | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $355.1M | $349.0M |
| Free Cash FlowOCF − Capex | $233.3M | $327.0M |
| FCF MarginFCF / Revenue | 15.6% | 35.4% |
| Capex IntensityCapex / Revenue | 8.1% | 2.4% |
| Cash ConversionOCF / Net Profit | 4.10× | 1.04× |
| TTM Free Cash FlowTrailing 4 quarters | $441.8M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $355.1M | — | ||
| Q3 25 | $302.0M | — | ||
| Q2 25 | $208.0M | $349.0M | ||
| Q1 25 | $1.6M | — | ||
| Q4 24 | $303.9M | — | ||
| Q3 24 | $239.2M | — | ||
| Q2 24 | $216.0M | $438.0M | ||
| Q1 24 | $18.5M | — |
| Q4 25 | $233.3M | — | ||
| Q3 25 | $207.5M | — | ||
| Q2 25 | $118.0M | $327.0M | ||
| Q1 25 | $-117.1M | — | ||
| Q4 24 | $241.5M | — | ||
| Q3 24 | $142.4M | — | ||
| Q2 24 | $80.9M | $430.0M | ||
| Q1 24 | $-119.4M | — |
| Q4 25 | 15.6% | — | ||
| Q3 25 | 13.4% | — | ||
| Q2 25 | 7.6% | 35.4% | ||
| Q1 25 | -8.2% | — | ||
| Q4 24 | 16.9% | — | ||
| Q3 24 | 9.3% | — | ||
| Q2 24 | 5.2% | 55.2% | ||
| Q1 24 | -8.7% | — |
| Q4 25 | 8.1% | — | ||
| Q3 25 | 6.1% | — | ||
| Q2 25 | 5.8% | 2.4% | ||
| Q1 25 | 8.3% | — | ||
| Q4 24 | 4.4% | — | ||
| Q3 24 | 6.3% | — | ||
| Q2 24 | 8.7% | 1.0% | ||
| Q1 24 | 10.0% | — |
| Q4 25 | 4.10× | — | ||
| Q3 25 | 2.54× | — | ||
| Q2 25 | 1.64× | 1.04× | ||
| Q1 25 | 0.03× | — | ||
| Q4 24 | 3.62× | — | ||
| Q3 24 | 2.08× | — | ||
| Q2 24 | 1.62× | 2.16× | ||
| Q1 24 | 0.27× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CLH
| Technical Services | $479.3M | 32% |
| Safetly Kleen Environmental Services | $252.9M | 17% |
| Fieldand Emergency Response | $246.6M | 16% |
| Products | $205.3M | 14% |
| Safety Kleen Sustainability Solutions Segment | $188.4M | 13% |
| Safety Kleen Oil | $132.6M | 9% |
GMAB
| Darzalex | $638.0M | 69% |
| Kesimpta | $108.0M | 12% |
| Net Product Sales | $101.0M | 11% |
| Other | $28.0M | 3% |
| Tepezza | $20.0M | 2% |
| Reimbursement Revenue | $13.0M | 1% |
| Bio N Tech | $11.0M | 1% |
| Abb Vie | $5.0M | 1% |
| Milestone Revenue | $1.0M | 0% |
